

## ICMJE DISCLOSURE FORM

Date: July 29, 2022

Your Name: Guodong Fu

Manuscript Title: Management of Thyroid Nodules with Indeterminate Fine-needle Aspiration Cytology: Histogram Analysis of Greyscale Sonograms or Molecular Testing of Residual Tissue from FNA Biopsies?

Manuscript number (if known): TCR-22-1919

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

*Guodong Fu reports that there is no conflicts of interest to declare.*

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

**Please summarize the above conflict of interest in the following box:**

None.

**Please place an "X" next to the following statement to indicate your agreement:**

I certify that I have answered every question and have not altered the wording of any of the questions on this

*Guodong Fu reports that there is no conflicts of interest to declare.*

**form.**

*Guodong Fu reports that there is no conflicts of interest to declare.*

## ICMJE DISCLOSURE FORM

Date: July 29, 2022

Your Name: Ian J Witterick

Manuscript Title: Management of Thyroid Nodules with Indeterminate Fine-needle Aspiration Cytology: Histogram Analysis of Greyscale Sonograms or Molecular Testing of Residual Tissue from FNA Biopsies

Manuscript number (if known): TCR-22-1919

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<u>None</u>	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>None</u>	
3	Royalties or licenses	<u>None</u>	

Ian Witterick reports that he receives payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Glaxo Smith Kline, Sanofi Regeneron and Novartis, serves President of Canadian Society of Otolaryngology – Head & Neck Surgery 2019-2021 and Head of Skull Base Section, American Head and Neck Society – 2021 to present as leadership or fiduciary role -unpaid, and holds Stock from Proteocyte Diagnostics Inc..

4	Consulting fees	____ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Glaxo Smith Kline Sanofi Regeneron Novartis	Advisory Board Advisory Board and lecture Lecture
6	Payment for expert testimony	____ None	
7	Support for attending meetings and/or travel	____ None	
8	Patents planned, issued or pending	____ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	____ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	President Section Head	Canadian Society of Otolaryngology – Head & Neck Surgery 2019-2021 - unpaid Skull Base Section, American Head and Neck Society – 2021 to present - unpaid
11	Stock or stock options	Stock	Proteocyte Diagnostics Inc.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	____ None	
13	Other financial or non-financial interests	____ None	

**Please summarize the above conflict of interest in the following box:**

Ian Witterick reports that he receives payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Glaxo Smith Kline, Sanofi Regeneron and Novartis, serves President of Canadian Society of Otolaryngology – Head & Neck Surgery 2019-2021 and Head of Skull Base Section, American Head and Neck Society – 2021 to present as leadership or fiduciary role -unpaid, and holds Stock from Proteocyte Diagnostics Inc..

Ian Witterick reports that he receives payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Glaxo Smith Kline, Sanofi Regeneron and Novartis, serves President of Canadian Society of Otolaryngology – Head & Neck Surgery 2019-2021 and Head of Skull Base Section, American Head and Neck Society – 2021 to present as leadership or fiduciary role -unpaid, and holds Stock from Proteocyte Diagnostics Inc..

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Ian Witterick reports that he receives payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Glaxo Smith Kline, Sanofi Regeneron and Novartis, serves President of Canadian Society of Otolaryngology – Head & Neck Surgery 2019-2021 and Head of Skull Base Section, American Head and Neck Society – 2021 to present as leadership or fiduciary role -unpaid, and holds Stock from Proteocyte Diagnostics Inc..